A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study
Open Access
- 28 October 2014
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 17 (2) , 152-160
Abstract
Aims: To assess the effects of renal impairment (RI) on the efficacy and safety of ipragliflozin in patients with type 2 diabetes mellitus (T2DM). Methods: A cohort of Japanese patients with T2DM and mild to moderate RI and poor glycaemic control, despite diet/exercise therapy alone or diet/exercise therapy in combination with an oral hypoglycaemic agent (an α‐glucosidase inhibitor, a sulfonylurea, or pioglitazone), were randomized in a double‐blind manner to 50 mg ipragliflozin or placebo once daily for 24 weeks. The patients continued open‐label ipragliflozin for a 28‐week extension period (total treatment duration: 52 weeks). Results: Ipragliflozin significantly decreased glycated haemoglobin (HbA1c) and fasting plasma glucose ( FPG ) levels and body weight from baseline to week 24 (last observation carried forward) compared with placebo in all patients with RI . The decreases in HbA1c and FPG levels were statistically significant in patients with mild RI , but not in patients with moderate RI . Ipragliflozin significantly reduced body weight in both RI groups. The improvements in glycaemic control were maintained in the 28‐week extension period. Ipragliflozin was associated with no clinically significant safety concerns, and its safety profiles were not influenced by the severity of RI . Conclusions: Ipragliflozin significantly improved glycaemic control and body weight in patients with T2DM with mild RI , but did not improve glycaemic control in patients with moderate RI . Ipragliflozin is a valid treatment option for patients with mild RI but not those with moderate RI .Keywords
This publication has 22 references indexed in Scilit:
- Renal Glucose HandlingDiabetes Care, 2013
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney diseaseDiabetes, Obesity and Metabolism, 2013
- Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metforminDiabetes, Obesity and Metabolism, 2012
- Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 DiabetesDiabetes Care, 2012
- International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program valuesDiabetology International, 2012
- International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program valuesJournal of Diabetes Investigation, 2012
- Revised Equations for Estimated GFR From Serum Creatinine in JapanAmerican Journal of Kidney Diseases, 2009
- Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implicationsKidney International, 2009
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 DiabetesDiabetes Care, 2008
- Active sugar transport in health and diseaseJournal of Internal Medicine, 2007